Press releases

Institute will drive sustainable innovation in three areas of environmental stewardship, furthering progress toward the company's 2030+ environmental, social and governance (ESG) commitments...

BD (Becton, Dickinson and Company) (NYSE: BDX) announced today that it will report financial results for its second quarter of fiscal year 2022 on Thursday, May 5, 2022. A news release will be...

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it has completed its spinoff of Embecta Corp. (embecta) (NASDAQ: EMBC), which...

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that Alberto Mas has informed the company of his intent to retire from BD, effective at...

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company today announced the early results and pricing terms of Morgan Stanley & Co. LLC's ("Morgan Stanley")...

FRANKLIN LAKES, N.J. (Mar 30, 2022) – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, recently released the BD Rhapsody™ TCR/BCR Multiomic Assay,...

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it has been named to Newsweek's inaugural list of "America's Most Trusted...

Record date for spin-off is March 22, 2022 "When Issued" trading of embecta common stock is expected to begin on March 21, 2022, under the ticker "EMBCV" BD expects the spin-off of embecta to be...

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company today announced that Morgan Stanley & Co. LLC ("Morgan Stanley") has commenced cash tender offers (each,...

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the appointment of William "Bill" Brown to its board of directors, effective Feb. 28, 2022.